NEW YORK , May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Prestige Consumer Healthcare Inc. ("Prestige" or the "Company") (NYSE: PBH). Such investors...
Prestige Consumer Healthcare executives projected a $1.1 billion revenue and adjusted diluted EPS of $4.54 for fiscal 2026, weeks before Q4 results fell materially short -- Levi & Korsinsky investigates...
Glancy Prongay Wolke & Rotter LLP , a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Prestige Consumer Healthcare (“Prestige...
Law Offices of Howard G. Smith announces an investigation on behalf of Prestige Consumer Healthcare (“Prestige Consumer” or the “Company”) (NYSE: PBH ) investors concerning the...
New York, New York--(Newsfile Corp. - May 18, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Prestige Consumer Healthcare Inc. (NYSE: PBH) ("Prestige Consumer...
The Law Offices of Frank R. Cruz announces an investigation of Prestige Consumer Healthcare (“Prestige Consumer” or the “Company”) (NYSE: PBH ) on behalf of investors concerning...
New York, New York--(Newsfile Corp. - May 15, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Prestige Consumer Healthcare Inc. ("Prestige Consumer Healthcare Inc.")...
Prestige Consumer Healthcare (NYSE:PBH) reported a weaker-than-expected fourth quarter as supply constraints in eye care and shipping disruptions tied to conflict in the Middle East weighed on sales, but...
Prestige Consumer Healthcare: Fiscal Q4 Earnings Snapshot
Reported revenues of $281.6 million in Q4 and $1,088.7 million in fiscal year 2026 Diluted EPS of $3.91 and Adjusted Diluted EPS of $4.38 in fiscal year 2026 Announces agreement to acquire LaCorium Health,...